Get the Stockscreener App
0.8755
5.49%
-0.0509
After Hours:
.90
0.0245
+2.80%
Inozyme Pharma Inc Stock (INZY) Forecast
The Inozyme Pharma Inc (INZY) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $5.4216, representing a +519.26% increase from the current price of $0.8755. The highest analyst price target is $7.0004, and the lowest is $3.8428.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month INZY Price Target
Average 4.732
(+440.49% Upside)
Is Inozyme Pharma Inc (INZY) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 33.51 | Neutral |
| STOCH(9,6) | 26.43 | Neutral |
| STOCHRSI(14) | 50.94 | Neutral |
| MACD(12,26) | -0.0998 | Buy |
| ADX(14) | 37.40 | Sell |
| William %R | -77.01 | Neutral |
| CCI(14) | -79.21 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.9412
Sell
|
0.9352
Sell
|
| MA20 |
0.9854
Sell
|
0.9988
Sell
|
| MA50 |
1.1886
Sell
|
1.3193
Sell
|
| MA100 |
1.9636
Sell
|
2.0015
Sell
|
| MA200 |
3.5077
Sell
|
2.9408
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, INZY could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 11 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on INZY, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 33.51 indicates that INZY is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 26.43 indicates that INZY is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 50.94 indicates that INZY is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 37.4 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -79.21 indicates that INZY is still oversold but not to an extreme extent.
Long-term INZY price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Inozyme Pharma Inc financial reports and earnings history, Inozyme Pharma Inc (INZY) stock could reach $9.8746 by 2030, $25.06 by 2040 and $16.54 by 2050. See the projected annual prices until 2050 of the Inozyme Pharma Inc stock below:
- Inozyme Pharma Inc (INZY) is expected to reach an average price of $19.41 in 2035, with a high prediction of $21.15 and a low estimate of $20.25. This indicates an $2,117% rise from the last recorded price of $0.8755.
- Inozyme Pharma Inc (INZY) stock is projected to chart a bullish course in 2040, with an average price target of $24.11, representing an $2,654% surge from its current level. The forecast ranges from a conservative $24.33 to a sky-high $25.06.
- Our analysts predict Inozyme Pharma Inc (INZY) to jump 2,297% by 2045, soaring from $20.89 to an average price of $20.99, potentially reaching $20.73. While $20.89 is the low estimate, the potential upside is significant.
- Inozyme Pharma Inc (INZY) stock is expected to climb by 2050, reaching an average of $16.49, a $1,784% jump from its current level. However, a wide range of estimates exists, with high and low targets of $16.54 and $16.52, respectively, highlighting the market's uncertainty.
Inozyme Pharma Inc Stock (INZY) Year by Year Forecast
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2025
Inozyme Pharma Inc Stock (INZY) is expected to reach an average price of $6.0165 in 2025, with a high prediction of $11.64 and a low estimate of $0.3885. This indicates an +587.20% rise from the last recorded price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $6.9504 | $3.8428 | $7.0004 | +693.87% |
| June, 2025 | $5.6956 | $4.9306 | $9.0755 | +550.55% |
| July, 2025 | $5.8233 | $4.2457 | $6.7531 | +565.14% |
| August, 2025 | $1.5035 | $0.7935 | $7.3859 | +71.73% |
| September, 2025 | $0.5663 | $0.4414 | $1.8986 | -35.32% |
| October, 2025 | $1.6535 | $0.3885 | $0.9288 | +88.86% |
| November, 2025 | $1.9433 | $1.9682 | $2.1208 | +121.96% |
| December, 2025 | $2.4705 | $2.8882 | $2.3156 | +182.19% |
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2026
The predicted value for Inozyme Pharma Inc (INZY) in 2026 is set at an average of $3.9979. Estimates vary from a peak of $5.4504 to a trough of $2.5454, indicating an +356.64% surge from the present price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.5503 | $2.5454 | $2.3429 | +77.08% |
| February, 2026 | $3.4601 | $2.5578 | $3.1327 | +295.22% |
| March, 2026 | $4.6699 | $4.1576 | $4.5699 | +433.40% |
| April, 2026 | $4.5971 | $4.6048 | $4.5274 | +425.09% |
| May, 2026 | $4.4069 | $4.5469 | $4.0846 | +403.36% |
| June, 2026 | $3.5567 | $3.9467 | $4.5618 | +306.25% |
| July, 2026 | $2.994 | $3.079 | $3.0491 | +241.97% |
| August, 2026 | $4.3438 | $4.3014 | $4.0963 | +396.15% |
| September, 2026 | $4.471 | $4.6412 | $4.4536 | +410.68% |
| October, 2026 | $4.8608 | $4.6385 | $4.6034 | +455.20% |
| November, 2026 | $5.5106 | $5.1357 | $5.3906 | +529.42% |
| December, 2026 | $5.6078 | $5.6429 | $5.4504 | +540.53% |
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Inozyme Pharma Inc (INZY) is $2.8301, with a high forecast of $5.5889 and a low forecast of $0.0713. This indicates an +223.25% increase from the last price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $5.6876 | $5.6553 | $5.4553 | +549.64% |
| February, 2027 | $4.9174 | $5.0974 | $5.5889 | +461.67% |
| March, 2027 | $3.6147 | $4.2272 | $4.0923 | +312.87% |
| April, 2027 | $3.5644 | $3.657 | $3.5197 | +307.13% |
| May, 2027 | $0.4942 | $1.4542 | $3.2919 | -43.55% |
| June, 2027 | $0.1285 | $0.2015 | $1.1785 | -85.32% |
| July, 2027 | $0.6487 | $0.1064 | $1.3311 | -25.90% |
| August, 2027 | $0.0411 | $0.0713 | $1.0313 | -95.31% |
| September, 2027 | $0.2983 | $0.266 | $1.8466 | -65.93% |
| October, 2027 | $0.2881 | $0.6032 | $0.2556 | -67.09% |
| November, 2027 | $0.7579 | $0.323 | $0.163 | -13.43% |
| December, 2027 | $1.9651 | $0.9653 | $1.3351 | +124.46% |
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2028
In 2028, Inozyme Pharma Inc (INZY) is projected to reach an average price of $3.118, with a high projection of $6.2154 and a low estimate of $0.0205. This indicates an +256.14% rise from the last price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.7749 | $1.8575 | $1.719 | +102.73% |
| February, 2028 | $0.6547 | $0.8647 | $1.2174 | -25.22% |
| March, 2028 | $0.042 | $0.1345 | $0.3422 | -95.21% |
| April, 2028 | $1.3783 | $0.0694 | $1.7083 | +57.42% |
| May, 2028 | $2.451 | $1.0508 | $3.101 | +179.96% |
| June, 2028 | $2.0612 | $1.6787 | $2.8737 | +135.43% |
| July, 2028 | $0.9414 | $0.8114 | $4.1413 | +7.53% |
| August, 2028 | $6.2249 | $0.654 | $4.36 | +611.01% |
| September, 2028 | $3.2855 | $0.0205 | $6.2154 | +275.27% |
| October, 2028 | $1.1241 | $0.6643 | $5.6957 | +28.39% |
| November, 2028 | $1.4785 | $2.9939 | $1.5112 | +68.88% |
| December, 2028 | $0.6719 | $0.7681 | $1.2719 | -23.26% |
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2029
The 2029 price forecast for Inozyme Pharma Inc Stock (INZY) is $4.1906 on average, with a high prediction of $8.1678 and a low estimate of $0.2133. This represents an +378.65% increase from the previous price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.7826 | $0.2133 | $4.017 | +103.61% |
| February, 2029 | $2.5178 | $2.6946 | $3.0578 | +187.58% |
| March, 2029 | $0.9518 | $1.6929 | $5.9829 | +8.71% |
| April, 2029 | $2.5514 | $3.0615 | $1.6516 | +191.42% |
| May, 2029 | $1.9558 | $2.4412 | $2.1509 | +123.40% |
| June, 2029 | $3.6354 | $3.6307 | $2.8405 | +315.24% |
| July, 2029 | $5.415 | $5.945 | $5.4708 | +518.51% |
| August, 2029 | $4.3095 | $4.6595 | $4.3297 | +392.23% |
| September, 2029 | $1.9791 | $3.4391 | $3.7928 | +126.05% |
| October, 2029 | $4.4836 | $4.824 | $4.9087 | +412.11% |
| November, 2029 | $8.3831 | $5.0985 | $6.6115 | +857.53% |
| December, 2029 | $9.4427 | $9.038 | $8.1678 | +978.55% |
Inozyme Pharma Inc Stock (INZY) Price Forecast for 2030
Inozyme Pharma Inc Stock (INZY) is expected to reach an average price of $11.73 in 2030, with a high forecast of $13.33 and a low forecast of $10.13. This signifies an +1,240% surge from the last price of $0.8755.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $9.4872 | $10.13 | $9.8746 | +983.63% |
| February, 2030 | $12.37 | $10.51 | $10.89 | +1,313% |
| March, 2030 | $11.98 | $12.29 | $11.65 | +1,268% |
| April, 2030 | $11.76 | $12.19 | $11.67 | +1,243% |
| May, 2030 | $12.24 | $11.62 | $11.49 | +1,298% |
| June, 2030 | $13.35 | $12.21 | $12.82 | +1,425% |
| July, 2030 | $13.00 | $13.28 | $13.33 | +1,385% |
| August, 2030 | $12.69 | $13.21 | $12.59 | +1,350% |
| September, 2030 | $12.99 | $12.92 | $12.85 | +1,384% |
| October, 2030 | $11.53 | $11.54 | $12.00 | +1,217% |
| November, 2030 | $12.13 | $11.07 | $11.95 | +1,285% |
| December, 2030 | $12.23 | $12.28 | $11.96 | +1,297% |
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):